PL EN


Preferences help
enabled [disable] Abstract
Number of results
2016 | 27 | 106 | 20-25
Article title

A review of medications used for treatment of obesity

Content
Title variants
PL
Przegląd najważniejszych preparatów stosowanych w leczeniu otyłości
Languages of publication
PL
Abstracts
EN
Obesity, which occurs both in rich as well as developing countries, is a chronic disease that can cause many serious illnesses. It has become a global health problem, which affects onethird of adult population in the world. To induce weight loss, profound lifestyle modification is required. In the case, when lifestyle changes alone are insufficient, pharmacotherapy can be helpful. Most of anti-obesity drugs (e. g. fenfluramine, sibutramine, rimonabant), which have been approved for treatment of obesity, were subsequently withdrawn from the market due to their adverse effects. In this manuscript, a short overview of currently available anti-obesity drugs like orlistat, lorcaserin, liragutide as well as phentermine/topiramate and naltrexone/ bupropion combination, was presented. Herein we focus on efficiency, mechanism of action and possible side effects of anti-obesity drugs. Finally, it was emphasized that better understanding of mechanisms involved in appetite regulation could be useful for developing novel, more effective and better tolerated anti-obesity drugs.
Discipline
Year
Volume
27
Issue
106
Pages
20-25
Physical description
References
  • 1. Zahorska­Markiewicz, B.;. Post. N. Med. 2009, 7, 494­497.
  • 2. Ng, M.; Fleming, T.; Robinson, M.; Thomson, B.; Graetz, N.; Margono, C. et al.;. Lancet 2014, 384, 766­781.
  • 3. Partyka, A.; Jastrzębska­Więsek, M.; Wróbel, D.; Wesołowska, A.;. Czas. Aptek. 2012, 44(2), 38­46.
  • 4. Daubresse, M., Alexander, G.C.; Int. J. Obes. (Lond). 2015, 39(3), 377­378.
  • 5. Kakkar, A.K.; Dahiya, N.;. Eur. J. Intern. Med. 2015, 26(2), 89­94.
  • 6. Gogga, P.; Karbowska, J.; Meissner, W.; Kochan, Z.;. Postępy Hig. Med. Dośw. 2011, 65, 255­262.
  • 7. Nylec, M.; Olszanecka­Glinianowicz, M.;. Postępy Hig. Med. Dośw. 2010, 64, 291­295.
  • 8. Korek, E.; Krauss, H.; Piątek, J.; Checińska, Z.;.Med. Ogólna Nauki Zdr. 2013, 19(2), 211­217.
  • 9. Kostulski, A.; Rebe­Jabłońska, J.;. Psychiatr. Psychol. Klin. 2007, 7(2), 108­116.
  • 10. Fijałkowski, F., Jarzyna, R.; Postepy Hig. Med. Dosw. 2010, 64, 231­243.
  • 1. Kusz­Rynkun, A.; Walicka, M.; MarcinowskaSuchowierska, E.;. Post. N. Med. 2013, 5, 44­48.
  • 12. Cheung B.M.Y.; Cheung, T.T.; Samaranayake N.R.;. Ther. Adv. Drug Saf. 2013, 4(4) 171­181.
  • 13. Bray, G.A.;. Best Pract. Res. Clin. Gastroenterol. 2014, 28(4), 665­684.
  • 14. Kim, G.W., Lin, J.E., Blomain, E.S., Waldman, S.A.; Clin. Pharmacol. Ther. 2014, 95(1), 53­66.
  • 15. Rodgers, R.J. Tschöp, M.H., Wilding, J.P.; Dis. Model. Mech. 2012, 5(5), 621­626.
  • 16. Anghelescu, I., Klawe, C., Benkert, O.: J. Clin. Psychopharmacol. 2000, 20(6), 716­7.
  • 17. Hainer, V.; Expert Opin. Pharmacother. 2014, 15(14), 1975­1978.
  • 18. Shyh, G., Cheng­Lai, A.; Cardiol. Rev. 2014, 22(1), 43­50.
  • 19. Zięba, R.;. Postępy Hig. Med. Dośw. 2007, 61, 612626.
  • 20. Butsch, W.S.;. Curr. Opin. Endocrinol. Diabetes Obes. 2015, 22(5), 360­366.
  • 21. Pucci, A.; Finer, N.;. Can. J. Cardiol. 2015, 31(2), 142­152.
  • 22. Med. Lett. Drugs Ther. 2015, 57(1471), 89­9.
  • 23. Toplak, H., Woodward, E., Yumuk, V., Oppert, J., Halford, J.C.G., Frühbeck, G.; Obes. Facts, 2015, 8, 166­174.
  • 24. Billes, S.K., Sinnayah, P., Cowley, M.A.; Pharmacol. Res. 2014, 84, 1­11.
Document Type
review
Publication order reference
YADDA identifier
bwmeta1.element.psjd-8a5cc979-eede-44b8-8a78-c464365bff03
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.